CCG-100602 T22062
Specifications
| 1mg/5mg/10mg/25mg/50mg/100mg |
Bioactivity:
CCG-100602 inhibits RhoA/C-mediated, SRF-driven luciferase expression in PC-3 prostate cancer cells (IC50 :9.8 ᄉM).
CAS nr:
1207113-88-9
Purity:
98%
Molecular Weight:
478,82
SMILES:
ClC1=CC=C(NC(C2CN(C(C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)=O)CCC2)=O)C=C1
Formula:
C21H17ClF6N2O2
Pathway:
GPCR/G Protein,MAPK,Cell Cycle/Checkpoint
Target:
Ras,Ras,Rho
